relapsed

Visugromab, a GDF-15 neutralizing IgG4 monoclonal antibody (mAb), demonstrates potent efficacy in treating PD-1/PD-L1 relapsed/refractory metastatic solid tumors [1].

Linvoseltamab, a bispecific antibody, targets both BCMA (TNFRSF17) and CD3 epsilon, demonstrating a favorable safety profile and promising efficacy in relapsed/refractory multiple myeloma (RRMM) [1][2].

Bersanlimab (BI-505) is a fully human monoclonal antibody targeting Intercellular Adhesion Molecule-1 (ICAM-1).Bersanlimab has anticancer properties and can be used to study relapsed/refractory multiple myeloma.

Glofitamab (RO7082859) is a novel bivalent antibody directed against CD20-binding T cells.Glofitamab promotes T cell proliferation and activation and tumor cell killing by binding to CD20 on malignant cells.Glofitamab can be used for the palliation of relapsed or refractory B-cell lymphomas.

Azintuxizumab, an IgG4 bispecific antibody, specifically targets the B-cell maturation antigen (BCMA) and shows promise for the investigation of relapsed/refractory multiple myeloma (RRMM) [1].

Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody against R-spondin 3 (RSPO3). Rosmantuzumab has potential antitumor activity and can be used to study advanced relapsed refractory solid tumors.

Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used to study relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) and refractory follicular lymphoma.

Brentuximab is a chimeric antibody targeting CD30 and is a naked antibody to Brentuximab vedotin.Brentuximab has antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.

Mezagitamab (TAK-079), an IgG1λ anti-CD38 monoclonal antibody, functions by depleting tumor cells that express CD38 through both antibody and complement-dependent cytotoxicity. It shows potential for use in the treatment of relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) [1] [2] [3].